Abstract The S1 subunit of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike protein contains an immunogenic receptor‐binding domain (RBD), which is a promising candidate for the development of a potential vaccine. This study demonstrated that intradermal delivery of an S‐RBD vaccine using a dissolvable microneedle skin patch can induce both significant B‐cell and significant T‐cell responses against S‐RBD. Importantly, the outcomes were comparable to that of conventional bolus injection.
All Keywords
【저자키워드】 COVID‐19, SARS‐CoV‐2, Spike protein, receptor‐binding domain, Microneedle, intradermal delivery, 【초록키워드】 Vaccine, coronavirus, outcome, SARS‐CoV‐2, RBD, S1 subunit, acute respiratory syndrome, immunogenic, receptor‐binding domain, B‐cell, demonstrated, induce, comparable, bolus injection, T‐cell response, 【제목키워드】 SARS‐CoV‐2, mice, Intradermal, cellular response, humoral, receptor‐binding domain, induce,
【저자키워드】 COVID‐19, SARS‐CoV‐2, Spike protein, receptor‐binding domain, Microneedle, intradermal delivery, 【초록키워드】 Vaccine, coronavirus, outcome, SARS‐CoV‐2, RBD, S1 subunit, acute respiratory syndrome, immunogenic, receptor‐binding domain, B‐cell, demonstrated, induce, comparable, bolus injection, T‐cell response, 【제목키워드】 SARS‐CoV‐2, mice, Intradermal, cellular response, humoral, receptor‐binding domain, induce,